source
- Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetesEli Lilly’s retatrutide, the incretin shot that has already proven its effectiveness against other assets on a cross-trial basis, has cemented its utility in a head-to-head trial, albeit in diabete…Endpoints · 13d ago↗ source
- Incyte's KRAS G12D inhibitor shows 89% response rate in early pancreatic cancer trialIn a Phase 1 study, Incyte tested its KRAS G12D inhibitor together with standard chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma carrying the G12D mutation. The combinati…